Search

Many changes have come over the business with the onset of globalization and the digitization of the economy, including the last two years. In addition, relevant changes have been caused by the COVID-19 pandemic, demonstrating the relevance of innovation management (IM) within organizations as a process to face these new realities. This article aims to present the main contributions on innovation management in small- and medium-sized enterprises (IM in SMEs). To determine the state-of-the-art innovation techniques, the study systematically reviews articles related to this subject using a bibliometric study approach between 1985 and 2019 using the Web of Science (WoS) database. The study analyzes and presents the most cited articles, the main authors, institutions, countries, and the most productive journals. Additionally, VOSviewer was used to provide a more in-depth analysis of the data obtained from the search. Among the main results, it is clear that the most productive universities and the most influential and productive authors are in the United States, leaving a relevant possibility of taking this analysis to different countries, mainly developing countries, to adjust adequate innovation processes according to the specific realities of each country. [ABSTRACT FROM AUTHOR]

It is now much discussed that Artificial Intelligence (AI) as a General-Purpose Technology (GPT) can resolve the efficiency problems of industries, including in pharmaceutical markets where productivity challenges continue in costs and time for new drug discovery. But did the COVID-19 pandemic inadvertently accelerate the pace of AI adoption in pharmaceutical innovation? We answer this question using novel data on pharmaceutical patents. We use two different databases to analyze abstracts of pharmaceutical patents applied in the USA. Topic modeling was used to identify patents with technical artifacts and classify them as treated group AI-adopting patents. An AI dictionary is used to match AI-related keywords in the patent abstracts. Subsequently, using a difference-in-differences research design we observe that both presence and count of AI keywords in pharmaceutical patents have increased with pandemic. An increase in AI is also related to reduced time taken from application to publication of a patent suggesting innovation efficiencies in the industry. Finally, we find that results are driven by firms that have already built AI capability in the past. Our results remain consistent with various robustness checks, and we conclude by discussing managerial and policy implications of our findings. • Did COVID-19 accelerate the pace of AI adoption in pharmaceutical patents? • We find supporting evidence for this question. • Both presence and count of AI keywords increased, and time to publish a patent decreased. • Results remain consistent with robustness checks and were time enduring. • Our findings have implications for the global health and innovation policy. [ABSTRACT FROM AUTHOR]